The George Washington University Medical Faculty Associates
Welcome,         Profile    Billing    Logout  
 15 Trials 
24 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gomberg-Maitland, Mardi
IMPAHCT-FUL, NCT05557942 / 2021-006864-25: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension

Terminated
3
186
Europe, Canada, US, RoW
AV-101
Aerovate Therapeutics, Aerovate Therapeutics Inc
Pulmonary Arterial Hypertension
08/24
08/24
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
2/3
202
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics, Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension
08/24
08/24
ELEVATE 2, NCT04712669 / 2020-004971-42: A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension

Completed
2
108
Europe, Canada, US, RoW
rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo
Altavant Sciences GmbH
Pulmonary Arterial Hypertension
06/23
08/23
Sen, Sabyasachi
NDKD, NCT06110130: Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With

Recruiting
4
60
US
Empagliflozin 10 MG, Placebo
Washington D.C. Veterans Affairs Medical Center, Boehringer Ingelheim
Chronic Kidney Diseases
12/25
12/26
Rothschild, Richard
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17004
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
NCT04502316: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

Recruiting
N/A
5000
US
Barostim™ System
CVRx, Inc.
Heart Failure
06/28
06/28
Hamed, Amen
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Recruiting
3
576
Canada, US
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis

Recruiting
3
698
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
11/27
11/27
NCT05495243: Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

Completed
2
40
US
ARINA-1, Placebo
Renovion, Inc.
Non-cystic Fibrosis Bronchiectasis
02/24
02/24
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Completed
2
48
US
AP-PA02, Placebo
Armata Pharmaceuticals, Inc.
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
07/24
08/24
PTK0796-NTM-20203, NCT04922554: Oral Omadacycline Vs. Placebo in Adults with NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Completed
2
66
US
Omadacycline Oral Tablet, Nuzyra, Placebo, placebo tablets
Paratek Pharmaceuticals Inc
Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
06/24
07/24
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Recruiting
2
75
US
TTI-101, Placebo
Tvardi Therapeutics, Incorporated
Idiopathic Pulmonary Fibrosis
03/25
07/25
Prasad, Poonam
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
Panjrath, Gurusher
NCT04502316: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

Recruiting
N/A
5000
US
Barostim™ System
CVRx, Inc.
Heart Failure
06/28
06/28
Porterfield, Christopher
NCT04088071: Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation

Recruiting
N/A
15000
US
Catheter ablation
Heart Rhythm Clinical and Research Solutions, LLC, Biosense Webster, Inc.
Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
12/27
12/27
NCT05860348: Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence

Recruiting
N/A
150
US
Barostim™ System
CVRx, Inc.
Heart Failure
05/28
05/28
NCT04502316: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

Recruiting
N/A
5000
US
Barostim™ System
CVRx, Inc.
Heart Failure
06/28
06/28
NCT05839873: Abbott Ventricular Tachycardia PAS

Recruiting
N/A
150
US
FlexAbility SE Ablation Catheter
Abbott Medical Devices
Ventricular Tachycardia
08/28
11/28
Quinones, Ana
ELEVATE 2, NCT04712669 / 2020-004971-42: A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension

Completed
2
108
Europe, Canada, US, RoW
rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo
Altavant Sciences GmbH
Pulmonary Arterial Hypertension
06/23
08/23
NCT02922764: A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Checkmark From a trial for solid tumors
Jun 2020 - Jun 2020: From a trial for solid tumors
Active, not recruiting
1
146
US
RGX-104, Ipilimumab, Docetaxel, Pembrolizumab, Carboplatin, Pemetrexed
Inspirna, Inc.
Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
12/24
12/24
Sidahmed, Alfateh
V-PLAQUE, NCT05360446: Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Active, not recruiting
3
608
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Coronary Artery Disease
01/27
01/27
NCT04502316: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

Recruiting
N/A
5000
US
Barostim™ System
CVRx, Inc.
Heart Failure
06/28
06/28
Huynh, Bao-An
KEYNOTE-A31, NCT04130542: Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

Active, not recruiting
1
276
US
LVGN6051, KEYTRUDA® (pembrolizumab)
Lyvgen Biopharma Holdings Limited, Merck Sharp & Dohme LLC
Cancer
12/25
12/25
Smith, Janellen
No trials found

Download Options